首页> 美国卫生研究院文献>Infection and Drug Resistance >In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates
【2h】

In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates

机译:环丙沙星/磷霉素联合治疗对耐环丙沙星的志贺氏菌分离株的体外和体内活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: Ciprofloxacin resistance (CIPR) for Shigella isolates is becoming more prevalent. This study systematically investigated the antibacterial activity of ciprofloxacin (CIP)/fosfomycin (FOS) combination in vitro and in vivo against CIPR S. flexneri isolates.>Method: Eighty CIPR S. flexneri isolates were selected for synergy studies by the microtiter plate checkerboard assay. Two S. flexneri isolates (, CIPRFOSR; GN120454, CIPRFOSS) were used to investigate the efficacy of the CIP/FOS combination by the time-kill methodology. Clinically relevant concentrations (CIP, 0.5, 1, or 2.5 μg/mL; FOS, 30, 150, or 300 μg/mL) were combined, and the colony counts were conducted at 3, 5, 8, and 24 hours. The in vivo activity of the CIP/FOS combination was assessed using a Galleria mellonella larvae model.>Results: In checkerboard assays, 31 strains (38.75%) showed synergy for the CIP/FOS combination. For the isolate , monotherapy with CIP or FOS at all concentrations produced little or no bacterial killing, while the CIP/FOS combination produced enhanced bacterial killing with FOS concentrations of 150 and 300 μg/mL, especially when combined with CIP at 2.5 μg/mL. For the isolate GN120454, the CIP/FOS combination at all concentrations produced more rapid and extensive killing (up to 5log10 colony forming units (CFU)/mL with many combinations) than with either antibiotic alone. Mortality at 96 hours was around 80% at approximately 104 CFU/larva for and GN120454. When CIP at 2.5 μg/mL was combined with FOS at 150 μg/mL for the bactericidal activity in vivo, the survival rates for CIP/FOS combination against -infected and GN120454-infected larvae were significantly higher than that of CIP (68.75% vs 25%, P=0.013; 81.25% vs 37.5%, P=0.012, respectively).>Conclusion: Against CIPR S. flexneri isolates, the CIP/FOS combination induced synergy, and increased bacterial killing in vitro and in a simple invertebrate model of infection.
机译:>目的:志贺菌菌株对环丙沙星的耐药性(CIP R )越来越普遍。这项研究系统地研究了环丙沙星(CIP)/磷霉素(FOS)组合在体外和体内对弗氏链球菌CIP R 的抗菌活性。>方法: 80个CIP <通过微量滴定板棋盘法选择了sup> R S. flexneri菌株进行协同研究。使用两个弗氏链球菌菌株(CIP R FOS R ; GN120454,CIP R FOS S )通过时间杀灭方法研究CIP / FOS组合的功效。合并临床相关浓度(CIP,0.5、1或2.5μg/ mL; FOS,30、150或300μg/ mL),并在3、5、8和24小时进行菌落计数。使用圆拱廊幼虫模型评估了CIP / FOS组合的体内活性。>结果:在棋盘试验中,有31个菌株(38.75%)对CIP / FOS组合具有协同作用。对于分离株,在所有浓度下均用CIP或FOS进行单一疗法几乎不会杀死细菌,而CIP / FOS组合则在150和300μg/ mL的FOS浓度下产生的细菌杀灭作用增强,尤其是与2.5μg/ mL的CIP结合使用时。对于分离物GN120454,与单独使用任何一种抗生素相比,所有浓度的CIP / FOS组合都能产生更快,更广泛的杀灭作用(对于许多组合而言,杀死率最高可达5log10菌落形成单位(CFU)/ mL)。对于GN120454和GN120454,在大约10 4 CFU /幼虫的情况下,96小时的死亡率约为80%。当将2.5μg/ mL的CIP与150μg/ mL的FOS结合以具有体内杀菌活性时,CIP / FOS组合抗感染和GN120454感染幼虫的存活率显着高于CIP(68.75%vs 25%,P = 0.013; 81.25%vs 37.5%,P = 0.012)。>结论:针对CIP R 福氏链球菌,CIP / FOS组合诱导协同作用,并在体外和简单的无脊椎动物感染模型中增加细菌杀伤力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号